McGill.CA / Cancer Prevention / Publications / Dr. Pollak's publications

2002 - 2003

2003

  1. Giovannucci E, Pollak M, Liu Y, Platz EA, Majeed N, Rimm EB, Willet WC. Nutritional predictors of insulin-like growth factor-I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev. 12: 84-9, 2003.
  2. Pollak MN, Foulkes W. Challenges to cancer control by screening. Nat Rev Cancer. 3: 297-303, 2003.
  3. Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 12: 412-8, 2003.
  4. Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res. 63: 3991-4, 2003.
  5. Nomura AM, Stemmermann GN, Lee J, Pollak MN. Serum insulin-like growth factor I and subsequent risk of colorectal cancer among Japanese-American men. Am J Epidemiol. 158: 424-31, 2003.
  6. Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN. Polymorphic variation at the -202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int J Cancer. 107: 60-4, 2003.
  7. Ismail HA, Pollak M, Behlouli H, Tanguay S, Bégin LR, Aprikian AG. Serum insulin-like growth factor (IGF) – 1 and IGF-binding protein-3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples. BJU Int. 92: 699-702, 2003.
  8. VanHouten JN, Dann P, Stewart AF, Watson CJ, Pollak M,Karaplis AC, Wysolmerski JJ. Mammary-specific deletion of parathyroid hormone-related protein preserves bone mass during lactation. J Clin Invest. 112: 1429-36, 2003.
  9. Nam RK, Zhang WW, Trachtenberg J, Jewett MA, Emami M, Vesprinin D, Chu W, Ho M, Sweet J, Evans A, Toi A, Pollak M, Narod SA. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev. 12: 1429-37, 2003.
  10. Hussain M, Banerjee M, Sarkar FH, Djuric Z, Pollak MN, Doerge D, Fontana J, Chinni S, Davis J, Forman J, Wood DP, Kucuk O. Soy isoflavones in the treatment of prostate cancer. Nutr Cancer. 47: 111-7, 2003

TOP OF PAGE

2002

  1. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst. 94: 1099-106, 2002.
  2. Giovannucci E, Pollak M. Risk of cancer after growth-hormone treatment. [editorial] Lancet. 360: 268-9, 2002.
  3. Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, Overmoyer B, Garg V, Ette E, Harding MW, Demetri GD. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res. 8: 670-8, 2002.
  4. Missmer SA, Haiman CA, Hunter DJ, Willett WC, Colditz GA, Speizer FE, Pollak MN, Hankinson SE. A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. Int J Cancer. 100: 332-6, 2002.
  5. Kucuk O, Sarkar FH, Sakr W, Khachik F, Djuric Z, Banerjee M, Pollak MN, Bertram JS, Wood DP. Lycopene in the treatment of prostate cancer. Pure and Applied Chemistry. 74: 1443-50, 2002.
  6. Holmes MD, Pollak MN, Willett WC, Hankinson SE. Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein-3 concentrations. Cancer Epidemiol Biomarkers Prev. 11: 852-61, 2002.
  7. Holmes MD, Pollak MN, Hankinson SE. Lifestyle correlates of plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 concentrations. Cancer Epidemiol Biomarkers Prev. 11: 862-7, 2002.
  8. Deitel K, Dantzer D, Ferguson P, Pollak M, Beamer W, Andrulis I, Bell R. Reduced growth of human sarcoma xenografts in hosts homozygous for the lit mutation. J Surg Oncol. 81: 75-9, 2002.
  9. Giovannucci E, Haiman CA, Platz EA, Hankinson SE, Pollak MN. Dinucleotide repeat in the insulin-like growth factor-I gene is not related to risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 11: 1509-10, 2002.
  10. Spitz MR, Barnett MJ, Goodman GE, Thornquist MD, Wu X, Pollak M. Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-carotene and Retinol Efficacy Trial Cohort. Cancer Epidemiol Biomarkers Prev. 11: 1413-8, 2002.
  11. Kucuk O, Sarkar FH, Djuric Z, Sakr W, Pollak MN, Khachik F, Banerjee M, Bertram JS, Wood DP Jr. Effects of lycopene supplementation in patients with localized prostate cancer. Exp Biol Med. 227: 881-5, 2002.
  12. Levitt RJ, Pollak M. Insulin-like growth factor-I antagonizes the anti-proliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. Cancer Res. 62: 7372-6, 2002.
  13. Camirand A, Lu Y, Pollak M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit. 8: BR521-6, 2002.
  14. Ismail AH, Pollak M, Behlouli H, Tanguay S, Bégin LR, Aprikian AG. Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy. J Urol. 168: 2426-30, 2002.
Back to top